Bristol-Myers Squibb buying Celgene in $74B deal
SUMMIT, N.J. (AP) — Bristol-Myers Squibb is spending $74 billion on fellow drugmaker Celgene in a deal aimed at stocking the combined company's development pipeline with cancer, immunology and cardiovascular treatments.
Bristol would gain the cancer treatment Revlimid in the cash-and-stock deal announced Thursday, as well as inflammatory disease treatments and several products close to launching.
- Business WireBristol-Myers Squibb to Take Part in the Cowen and Company 39th Annual Health Care ConferenceMarch 5, 2019
- Business WireBristol-Myers Squibb to Take Part in Guggenheim Healthcare Talks Idea ForumFebruary 7, 2019
- BusinessWireBristol-Myers Squibb to Participate in the 37th Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2019
- BusinessWireBristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care ConferenceSeptember 6, 2018